MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

As the next round of the Trans-Pacific Partnership Agreement (TPP) negotiations continues in Malaysia, MSF urges negotiating countries to reject provisions that threaten to restrict access to affordable medicines for millions of people.

More >

There has been new momentum at the highest political levels to put plans into place that will make the most use of the recent science showing ART itself both saves lives and stops HIV from spreading. International funding, however, remains largely stagnant across the board and will need to be increased to achieve the goals of saving more lives through treatment, while dramatically reducing HIV transmission.

More >

Unless damaging provisions are removed before negotiations are finalized, the TPP agreement is on track to become the most harmful trade pact ever for access to medicines in developing countries.

More >

Over the last few years, new vaccines to fight an increased range of childhood diseases have come to market.

More >

Immunization is one of the most effective ways of saving young lives, yet every year one in five children born—22 million—is left without this basic protection from disease.

More >

Encompassing eleven countries and slated for further expansion across the Asia Pacific region, the Trans-Pacific Partnership Agreement (TPP) is a regional trade agreement that will set the standard for 21st-century trade agreements going forward.

More >

Despite recent advances, there's still a need to make noise about "the silent disease."

More >

Read MSF's submission to the US trade representative on the 2012 Special 301 review process, which affects accessibility of medicines and important diagnostic tools.

More >

Read Novartis's statements on its generic medicines court case, and learn why they're wrong.

More >

Learn more about why Novartis is taking India to court over the production of affordable generic medicines.

More >

Pages